{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:11:13Z","timestamp":1784826673073,"version":"3.55.0"},"reference-count":38,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"unspecified","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Cancer Institute","award":["P30 CA093373"],"award-info":[{"award-number":["P30 CA093373"]}]},{"name":"National Institute of Health","award":["S10 RR026825"],"award-info":[{"award-number":["S10 RR026825"]}]},{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"crossref","award":["CIRM TRAN1-13996"],"award-info":[{"award-number":["CIRM TRAN1-13996"]}],"id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,6,30]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chimeric antigen receptor (CAR) T cells are highly potent therapies approved by the U.S. Food and Drug Administration (FDA) for several hematological malignancies. However, efficacy remains variable due to resistance, antigen modulation, systemic toxicities, and relapse. Developing improved CAR T cell therapies relies on preclinical models that accurately predict clinical outcomes. For this purpose, immortalized tumor cell lines, such as the Burkitt\u2019s lymphoma line Raji, are commonly used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>CD19-targeting CAR (CAR19) and non-transduced (NT) human T cells were co-cultured with target cell lines in vitro to assess T cell cytotoxicity, cytokine production, activation, and proliferation. Major histocompatibility complex (MHC) class I and II blocking antibodies and TCR knockout (KO) T cells were used to validate T cell receptor interactions. In vivo, Raji wild-type (wt) or CD19 KO tumor-bearing mice were treated with CAR19 or NT T cells, and survival, tumor burden, serum cytokines, and T cell phenotype in tissues were analyzed. Statistical analyses using either paired\/paired ratio\/unpaired two-tailed Student\u2019s t tests, two-way analysis of variance, and log-rank (Mantel-Cox) tests were performed using GraphPad Prism 9.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We report that T cells generated from multiple different donors exhibit not only strong CAR-mediated cytotoxicity against CD19-expressing Raji WT cells but also, unexpectedly, CAR-independent reactivity against Raji CD19 KO cells. This reactivity was observed both in vitro and in vivo, and was associated with pro-inflammatory cytokine secretion and upregulation of T cell activation markers, consistent with endogenous T cell receptor (TCR) engagement. NT T cells displayed similar activation, cytotoxic, and cytokine responses against Raji cells. These effects failed to occur using other B cell leukemia\/lymphoma or solid tumor cell lines in vitro. Both CD4+ and\u2009CD8+ T\u2009cell populations contributed to this alloreactive response, which could be attenuated by blockade of MHC class I or II, highlighting a TCR:MHC-dependent mechanism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings demonstrate that certain tumor lines can elicit strong allogeneic T cell responses independent of CAR specificity, revealing an important limitation of commonly used preclinical models and highlighting the potential for false-positive assessments of CAR T cell efficacy. Furthermore, these results highlight the importance of validating tumor models for alloreactivity prior to use in preclinical testing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-015074","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:40:19Z","timestamp":1784824819000},"page":"e015074","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Intrinsic tumor cell line immunogenicity may drive CAR-independent T cell responses and confound CAR T cell preclinical modeling"],"prefix":"10.1136","volume":"14","author":[{"given":"Michael K","family":"Sheng","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of California Davis School of Medicine, Sacramento, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wahed A","family":"Firoz","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California Davis School of Medicine, Sacramento, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Loi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California Davis School of Medicine, Sacramento, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logan V","family":"Vick","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California Davis School of Medicine, Sacramento, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig P","family":"Collins","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California Davis School of Medicine, Sacramento, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan N","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California Davis School of Medicine, Sacramento, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L","family":"Schmeling","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuchi","family":"Gulati","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J","family":"Judge","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of California Davis School of Medicine, Sacramento, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-5418","authenticated-orcid":false,"given":"Robert J","family":"Canter","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of California Davis School of Medicine, Sacramento, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arta M","family":"Monjazeb","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California Davis School of Medicine, Sacramento, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony E","family":"Zamora","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2793-401X","authenticated-orcid":false,"given":"William J","family":"Murphy","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California Davis School of Medicine, Sacramento, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"2026072309401266000_14.7.e015074.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"2026072309401266000_14.7.e015074.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"2026072309401266000_14.7.e015074.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0"},{"key":"2026072309401266000_14.7.e015074.4","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"2026072309401266000_14.7.e015074.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0184-6"},{"key":"2026072309401266000_14.7.e015074.6","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"2026072309401266000_14.7.e015074.7","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05707-3"},{"key":"2026072309401266000_14.7.e015074.8","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01380-x"},{"key":"2026072309401266000_14.7.e015074.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.09.021"},{"key":"2026072309401266000_14.7.e015074.10","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO-24-02081","article-title":"Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy","volume":"43","author":"Ouladan","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026072309401266000_14.7.e015074.11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers18091412","article-title":"Determinants of Chimeric Antigen Receptor (CAR) T Cell Success: In Vitro and In Vivo Preclinical Assessment","volume":"18","author":"Sheng","year":"2026","journal-title":"Cancers (Basel)"},{"key":"2026072309401266000_14.7.e015074.12","doi-asserted-by":"publisher","DOI":"10.3109\/10428199809059223"},{"key":"2026072309401266000_14.7.e015074.13","doi-asserted-by":"crossref","first-page":"735","DOI":"10.21037\/atm.2019.12.03","article-title":"Preclinical safety evaluation of chimeric antigen receptor-modified T cells against CD19 in NSG mice","volume":"7","author":"Wen","year":"2019","journal-title":"Ann Transl Med"},{"key":"2026072309401266000_14.7.e015074.14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200317601"},{"key":"2026072309401266000_14.7.e015074.15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-016410"},{"key":"2026072309401266000_14.7.e015074.16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00624","article-title":"Donor Allospecific CD44high Central Memory T Cells Have Decreased Ability to Mediate Graft-vs.-Host Disease","volume":"10","author":"Huang","year":"2019","journal-title":"Front Immunol"},{"key":"2026072309401266000_14.7.e015074.17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-109678"},{"key":"2026072309401266000_14.7.e015074.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03161.x"},{"key":"2026072309401266000_14.7.e015074.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.12.711"},{"key":"2026072309401266000_14.7.e015074.20","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nm.4258","article-title":"Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity","volume":"23","author":"Ghosh","year":"2017","journal-title":"Nat Med"},{"key":"2026072309401266000_14.7.e015074.21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.omtm.2022.08.008","article-title":"Applying a clinical lens to animal models of CAR-T cell therapies","volume":"27","author":"Duncan","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2026072309401266000_14.7.e015074.22","doi-asserted-by":"crossref","DOI":"10.3390\/cells13020146","article-title":"Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?","volume":"13","author":"Lonez","year":"2024","journal-title":"Cells"},{"key":"2026072309401266000_14.7.e015074.23","doi-asserted-by":"crossref","first-page":"100677","DOI":"10.1016\/j.medj.2025.100677","article-title":"Emerging trends in clinical allogeneic CAR cell therapy","volume":"6","author":"Li","year":"2025","journal-title":"Med"},{"key":"2026072309401266000_14.7.e015074.24","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3838"},{"key":"2026072309401266000_14.7.e015074.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-023-00789-0"},{"key":"2026072309401266000_14.7.e015074.26","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-023-04824-z","article-title":"Spontaneous tumor regression mediated by human T cells in a humanized immune system mouse model","volume":"6","author":"Patel","year":"2023","journal-title":"Commun Biol"},{"key":"2026072309401266000_14.7.e015074.27","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-023-04812-3","article-title":"Human CD4 cytotoxic T lymphocytes mediate potent tumor control in humanized immune system mice","volume":"6","author":"Lin","year":"2023","journal-title":"Commun Biol"},{"key":"2026072309401266000_14.7.e015074.28","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood.2020005185","article-title":"Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR\/Cas9-mediated TCR knockout CAR","volume":"136","author":"Stenger","year":"2020","journal-title":"Blood"},{"key":"2026072309401266000_14.7.e015074.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63184-7"},{"key":"2026072309401266000_14.7.e015074.30","doi-asserted-by":"crossref","first-page":"41033","DOI":"10.18632\/oncotarget.5708","article-title":"The copy number of Epstein-Barr virus latent genome correlates with the oncogenicity by the activation level of LMP1 and NF-\u03baB","volume":"6","author":"Zuo","year":"2015","journal-title":"Oncotarget"},{"key":"2026072309401266000_14.7.e015074.31","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/10.4.499"},{"key":"2026072309401266000_14.7.e015074.32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-278218"},{"key":"2026072309401266000_14.7.e015074.33","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.3.1363"},{"key":"2026072309401266000_14.7.e015074.34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001708","article-title":"Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies","volume":"3","author":"Waibler","year":"2008","journal-title":"PLoS One"},{"key":"2026072309401266000_14.7.e015074.35","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.4049\/jimmunol.142.9.3151","article-title":"Binding of staphylococcal enterotoxin A to HLA-DR on B cell lines","volume":"142","author":"Fischer","year":"1989","journal-title":"J Immunol"},{"key":"2026072309401266000_14.7.e015074.36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.11.4210"},{"key":"2026072309401266000_14.7.e015074.37","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(01)00565-8"},{"key":"2026072309401266000_14.7.e015074.38","doi-asserted-by":"crossref","DOI":"10.1038\/srep43833","article-title":"Efficient and reliable establishment of lymphoblastoid cell lines by Epstein-Barr virus transformation from a limited amount of peripheral blood","volume":"7","author":"Omi","year":"2017","journal-title":"Sci Rep"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-015074","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:40:23Z","timestamp":1784824823000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-015074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,23]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/jitc-2026-015074"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-015074","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}